tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Agios Pharmaceuticals price target raised to $25 from $20 at JPMorgan
PremiumThe FlyAgios Pharmaceuticals price target raised to $25 from $20 at JPMorgan
27d ago
Agios Pharma: Broad Aqvesme Label, Premium Pricing, and Manageable Safety Profile Support Buy Rating and 54.5% Upside Potential
Premium
Ratings
Agios Pharma: Broad Aqvesme Label, Premium Pricing, and Manageable Safety Profile Support Buy Rating and 54.5% Upside Potential
1M ago
Agios Pharmaceuticals: Thalassemia Approval, Premium Pricing, and Manageable REMS Drive Higher Target and Undervalued Buy Thesis
Premium
Ratings
Agios Pharmaceuticals: Thalassemia Approval, Premium Pricing, and Manageable REMS Drive Higher Target and Undervalued Buy Thesis
1M ago
Agios Pharmaceuticals’ Aqvesme to be introduced at $425K per patient per year
PremiumThe FlyAgios Pharmaceuticals’ Aqvesme to be introduced at $425K per patient per year
1M ago
Agios Pharmaceuticals price target raised to $34 from $32 at BofA
Premium
The Fly
Agios Pharmaceuticals price target raised to $34 from $32 at BofA
1M ago
FDA approves Agios Pharmaceuticals’ Aqvesme in anemia patients
Premium
The Fly
FDA approves Agios Pharmaceuticals’ Aqvesme in anemia patients
1M ago
Agios Pharmaceuticals says FDA has not yet issued decision for mitapivat sNDA
PremiumThe FlyAgios Pharmaceuticals says FDA has not yet issued decision for mitapivat sNDA
2M ago
Agios Pharmaceuticals initiated with a Buy at Citi (yesterday)
Premium
The Fly
Agios Pharmaceuticals initiated with a Buy at Citi (yesterday)
2M ago
Agios Pharmaceuticals initiated with a Buy at Truist
Premium
The Fly
Agios Pharmaceuticals initiated with a Buy at Truist
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100